AC Immune SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACIU Nasdaq 8731 https://www.acimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AC Immune SA

AC Immune Holds Annual General Meeting of Shareholders - Jun 24th, 2022 8:30 pm
10 Unknown Biotech Stocks That Can Explode in 2022 - Jun 21st, 2022 2:35 pm
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen - Jun 17th, 2022 12:31 pm
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients - Jun 16th, 2022 12:20 pm
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals - Jun 16th, 2022 10:39 am
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease - Jun 16th, 2022 5:00 am
We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate - Jun 1st, 2022 12:26 pm
AC Immune to Present at the 2022 Jefferies Healthcare Conference - May 31st, 2022 11:30 am
AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award - May 17th, 2022 1:00 pm
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology - May 9th, 2022 3:00 pm
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update - Apr 28th, 2022 11:30 am
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference - Apr 27th, 2022 11:55 am
AC Immune Reports Changes to Senior Management - Apr 8th, 2022 11:30 am
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases - Mar 30th, 2022 11:58 am
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update - Mar 22nd, 2022 11:30 am
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases - Mar 21st, 2022 11:30 am
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference - Mar 16th, 2022 11:41 am
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs - Feb 28th, 2022 12:30 pm
Could The AC Immune SA (NASDAQ:ACIU) Ownership Structure Tell Us Something Useful? - Feb 21st, 2022 9:30 am
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial - Feb 15th, 2022 7:54 pm